Tenofovir, Emtricitabine Intracellular and Plasma, and Efavirenz Plasma Concentration Decay Following Drug Intake Cessation: Implications for HIV Treatment and Prevention
暂无分享,去创建一个
David Back | Victoria Watson | B. Gazzard | M. Boffito | D. Back | G. Moyle | Brian Gazzard | Graeme Moyle | Marta Boffito | Akil Jackson | John Tjia | Alieu Ammara | Malika Mohabeer | A. Jackson | J. Tjia | V. Watson | Alieu Ammara | Malika Mohabeer | A. Ammara
[1] P. Piliero. Pharmacokinetic Properties of Nucleoside/Nucleotide Reverse Transcriptase Inhibitors , 2004, Journal of acquired immune deficiency syndromes.
[2] F. Rousseau,et al. Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection. , 2004, AIDS research and human retroviruses.
[3] S. Khoo,et al. Stopping antiretroviral therapy , 2007, AIDS.
[4] S. Khoo,et al. Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons , 2008, Current opinion in HIV and AIDS.
[5] K. Tashima,et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] David V Glidden,et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. , 2010, The New England journal of medicine.
[7] S. Broder,et al. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. , 1993, The Journal of clinical investigation.
[8] D. Katzenstein,et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. , 2011, The Journal of infectious diseases.
[9] C. Aquilante,et al. Clinical and Genetic Determinants of Intracellular Tenofovir Diphosphate Concentrations in HIV-Infected Patients , 2008, Journal of acquired immune deficiency syndromes.
[10] B. Kearney,et al. Intracellular Pharmacokinetics of Tenofovir Diphosphate, Carbovir Triphosphate, and Lamivudine Triphosphate in Patients Receiving Triple-Nucleoside Regimens , 2005, Journal of acquired immune deficiency syndromes.
[11] R. Grant,et al. Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. , 2011, The Journal of antimicrobial chemotherapy.
[12] B. Gazzard,et al. Pharmacokinetics and Safety of Etravirine Administered Once or Twice Daily After 2 Weeks Treatment With Efavirenz in Healthy Volunteers , 2009, Journal of acquired immune deficiency syndromes.
[13] Martin Fortin,et al. Managing patients with multimorbidity: systematic review of interventions in primary care and community settings , 2012, BMJ : British Medical Journal.
[14] Matthias Cavassini,et al. Correlates of Self-Reported Nonadherence to Antiretroviral Therapy in HIV-Infected Patients: The Swiss HIV Cohort Study , 2006, Journal of acquired immune deficiency syndromes.
[15] C. Leen,et al. 7.0 Managing virological failure , 2012, HIV medicine.
[16] R. V. van Schaik,et al. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. , 2006, British journal of clinical pharmacology.
[17] T. Cihlar,et al. Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors. , 2002, Antiviral research.